Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypo-Mag: Intra-arterial Magnesium Sulfate in Acute Ischemic Stroke
NCT06760195Phase 1Not yet recruiting
- Sponsor
- Capital Medical University
- Start
- Jan 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of magnesium sulfate in ischemic stroke, sponsored by Capital Medical University. Primary endpoint: Mortality at 90 days. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
magnesium sulfate
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06760195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06760195.